Global Oropharyngeal Candidiasis Market, By Type, By Treatment, By Route of Administration, By Distribution Channel, By Geography

Description

Global oropharyngeal candidiasis market was valued at US$ 456 Mn in 2023 and is expected to reach US$ 630.4 Mn by 2031, exhibiting at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 456 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	4.10%	2030/2031 Value Projection:	US$ 630.4 Mn

Figure 1. Global Oropharyngeal Candidiasis Market Share (%), By Region, 2024

Global Oropharyngeal Candidiasis Market - IMG1

Oropharyngeal candidiasis (OPC) which is also commonly known as oral thrush, is a fungal infection which is caused by the overgrowth of Candida species, predominantly Candida albicans, in the oral and pharyngeal mucous membranes. While Candida is a normal component of the oral microbiota, certain conditions can disrupt the delicate balance of microorganisms, thereby leading to its excessive proliferation. It is frequently observed in individuals with compromised immune systems, such as those with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), undergoing chemotherapy, or taking broad-spectrum antibiotics. It can also occur in patients with diabetes or those who use corticosteroids or wear dentures. The infection is typically characterized by white patches on the tongue, inner cheeks, and roof of the mouth, gums, tonsils, or the back of the throat. These lesions can be slightly raised and may cause discomfort or difficulty in swallowing when severe. It is a condition that has garnered significant attention within medical research and patient care due to its pervasive nature in immunocompromised populations. While Candida is a standard tenant of the oral flora among many individuals without causing harm, various circumstances, such as immunodeficiency, extended antibiotic use, diabetes, and certain medical therapies, can predispose individuals to this opportunistic fungal infection. The hallmark symptoms of this infection consist of creamy white lesions that appear on the mucosal surfaces of the oral cavity and the throat. These lesions are sometimes accompanied by discomfort and can impede proper nutrition and swallowing when they are extensive. The treatment landscape for OPC typically involves antifungal medications, with an emphasis on addressing any underlying conditions that may have led to the fungal overgrowth. Market analysis reveals that the therapeutic area for this condition is significantly influenced by the high prevalence of diabetes and HIV/AIDS globally, with a resultant increase in demand for efficacious antifungal therapies.

Market Dynamics:

Global oropharyngeal candidiasis market is driven by the rising prevalence of HIV/AIDS along with a growing elderly population that is susceptible to fungal infections. Moreover, increasingly aggressive tumor-directed therapies along with frequent use of broad-spectrum antibiotic and corticosteroid therapies spur the risk of oral thrush. However, the market potentially faces restraints from rising generics competition and availability of alternate treatment options.

Key features of the study:

This report provides in-depth analysis of the global oropharyngeal candidiasis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global oropharyngeal candidiasis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer, Wockhardt, Ranbaxy Laboratories, Bristol Laboratories, Glenmark Pharmaceuticals Ltd, and GlaxoSmithKline.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global oropharyngeal candidiasis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oropharyngeal candidiasis market.

Detailed Segmentation:

Global Oropharyngeal Candidiasis Market, By Type
- Pseudomembranous
- Erythematous
- Hyperplastic
Global Oropharyngeal Candidiasis Market, By Treatment
- Anti-fungal
- Immune-modulators
Global Oropharyngeal Candidiasis Market, By Route of Administration
- Oral
- Topical
- Others
Global Oropharyngeal Candidiasis Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Oropharyngeal Candidiasis Market, By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Top Companies in Global Oropharyngeal Candidiasis Market:
- Bayer AG
- Teva Pharmaceuticals
- Stellar Pharma
- Pfizer
- Wockhardt
- Ranbaxy Laboratories
- Bristol Laboratories
- Glenmark Pharmaceuticals Ltd
- GlaxoSmithKline

Product Code: CMI6617

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Oropharyngeal Candidiasis, By Type
- Market Oropharyngeal Candidiasis, By Treatment
- Market Oropharyngeal Candidiasis, By Route of Administration
- Market Oropharyngeal Candidiasis, By Distribution Channel
- Market Oropharyngeal Candidiasis, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
Increasing prevalence of HIV/AIDS
Rising research funding and projects
Increasing number of healthcare facilities
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Oropharyngeal Candidiasis Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Oropharyngeal Candidiasis Market, By Type, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Pseudomembranous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Erythematous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Hyperplastic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Oropharyngeal Candidiasis Market, By Treatment, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020-2031
- Segment Trends
Anti-fungal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Immune-modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Oropharyngeal Candidiasis Market, By Route of Administration, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020-2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Oropharyngeal Candidiasis Market, By Distribution Channel, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020-2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

9. Global Oropharyngeal Candidiasis Market, By Region, 2019-2031, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019 -2031
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031 ,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Mn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031, (US$ Mn)
South Africa
North Africa
Central Africa

10. Competitive Landscape

Company Profile
- Bayer AG
Company Highlights
Type Portfolio
Key Developments
Financial Performance
Strategies
- Teva Pharmaceuticals
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Stellar Pharma
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Pfizer
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Wockhardt
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Ranbaxy Laboratories
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Bristol Laboratories
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- Glenmark Pharmaceutical Ltd
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
- GlaxoSmithKline
Company Highlights
Type Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

11. Section

References
Research Methodology
About us